A preliminary study of growth hormone therapy for Crohn's disease.

BACKGROUND Crohn's disease is a chronic inflammatory disorder of the bowel. In a preliminary study, we evaluated whether the administration of growth hormone (somatropin) as well as a high-protein diet would ameliorate the symptoms of the disease. METHODS We randomly assigned 37 adults with moderate-to-severe active Crohn's disease to four months of self-administered injections of growth hormone (loading dose, 5 mg per day subcutaneously for one week, followed by a maintenance dose of 1.5 mg per day) or placebo. We instructed all patients to increase their protein intake to at least 2 g per kilogram of body weight per day. Patients continued to be treated by their usual physicians and to receive other medications for Crohn's disease. The primary end point was the change in scores on the Crohn's Disease Activity Index from base line to month 4. Scores can range from 0 to 600, with higher scores indicating more disease activity. RESULTS At base line, the mean (+/-SD) score on the Crohn's Disease Activity Index was somewhat higher among the 19 patients in the growth hormone group than among the 18 patients in the placebo group (287+/-134 vs. 213+/-120, P=0.09). Three patients in the placebo group withdrew before their first follow-up visit and were not included in the data analysis. At four months, the Crohn's Disease Activity Index score had decreased by a mean of 143+/-144 points in the growth hormone group, as compared with a decrease of 19+/-63 points in the placebo group (P=0.004). Side effects in the growth hormone group included edema (in 10 patients) and headache (in 5) and usually resolved within the first month of treatment. CONCLUSIONS Our preliminary study suggests that growth hormone may be a beneficial treatment for patients with Crohn's disease.

[1]  D. Shulman,et al.  Effects of Short‐Term Growth Hormone Therapy in Rats Undergoing 75% Small Intestinal Resection , 1992, Journal of pediatric gastroenterology and nutrition.

[2]  M. Elia,et al.  Amino acid metabolism in muscle and in the whole body of man before and after ingestion of a single mixed meal. , 1989, The American journal of clinical nutrition.

[3]  Sartor Rb.  Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. , 1997 .

[4]  A. Brett.  New Approaches to Crohn's Disease , 2000 .

[5]  B. Ludviksson,et al.  The Pathogenesis of Mucosal Inflammation in Murine Models of Inflammatory Bowel Disease and Crohn Disease , 1998, Annals of Internal Medicine.

[6]  W. Souba,et al.  Growth Hormone Enhances Amino Acid Uptake by the Human Small Intestine , 1994, Annals of surgery.

[7]  M. Mäki,et al.  Exclusive Whole Protein Enteral Diet Versus Prednisolone in the Treatment of Acute Crohn's Disease in Children , 1994, Journal of pediatric gastroenterology and nutrition.

[8]  H. Sax,et al.  Epidermal growth factor and human growth hormone accelerate adaptation after massive enterectomy in an additive, nutrient-dependent, and site-specific fashion. , 1997, Surgery.

[9]  J. Rotter,et al.  Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. , 1986, Annals of internal medicine.

[10]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[11]  T. Ziegler,et al.  A New Treatment for Patients with Short‐Bowel Syndrome Growth Hormone, Glutamine, and a Modified Diet , 1995, Annals of surgery.

[12]  A. Casola,et al.  In Vivo and In Vitro Effects of Human Growth Hormone on Rat Intestinal Ion Transport , 1995, Pediatric Research.

[13]  A. Hofmann,et al.  Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. , 1972, Gastroenterology.

[14]  P. Lund.  Molecular Basis of Intestinal Adaptation: The Role of the Insulin‐like Growth Factor System , 1998, Annals of the New York Academy of Sciences.

[15]  S. Hanauer,et al.  Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. , 1999, Inflammatory bowel diseases.

[16]  P. Carroll,et al.  Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review , 1998 .

[17]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[18]  Sartor Rb.  New therapeutic approaches to Crohn's disease. , 2000 .

[19]  J. Rombeau,et al.  Insulin-like growth factor-I (IGF-I) and glutamine improve structure and function in the small bowel allograft. , 1995, The Journal of surgical research.

[20]  K. Barrett,et al.  Phosphatidylinositol 3-Kinase-dependent Pathways Oppose Fas-induced Apoptosis and Limit Chloride Secretion in Human Intestinal Epithelial Cells , 2001, The Journal of Biological Chemistry.